证券代码：002773 证券简称：康弘药业 公告编号：2025-069 成都康弘药业集团股份有限公司 关于子公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）子 公司成都弘基生物科技有限公司（以下简称"弘基生物"）收到国家 药品监督管理局签发的《药物临床试验批准通知书》。现将相关情况 公告如下： 一． 药品基本信息 药品名称：KH658 眼用注射液 剂型：注射剂 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定的不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 成都康弘药业集团股份有限公司董事会 受理号：CXSL2500823、CXSL2500824、CXSL2500825、CXSL2500826 审批结论：同意开展糖尿病黄斑水肿（DME）、糖尿病视网膜病 变（DR）的临床试验。 二． 产品简介 KH658 眼用注射液是弘基生物自主研发的基因治疗创新产品，属 于治疗用生物制品 1 类，分别于 2024 年 4 月 28 日获得中国药品监督 管理局 ...

成都康弘药业集团股份有限公司董事会秘书邓康：康弘药业从成立开始，创新就是刻在企业DNA（基 因）里面的。 0:00 ...

Group 1 - The National Healthcare Security Administration announced the inclusion of Kangbaxipu Eye Injection (brand name "Langmu") in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, recognizing its innovation and clinical value [1][2] - Kangbaxipu is currently the only domestic innovative drug covering four major indications for retinal diseases, which will enhance the stability and accessibility of medication for patients [1] - The new drug catalog will be implemented starting January 1, 2026, but the specific impact on the company's current operating performance cannot be accurately estimated at this time [1]

Group 1 - Aosaikang's product, Liraglutide tablets (brand name: Aoyixin), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Kanghong Pharmaceutical's product, Conbercept eye injection (brand name: Langmu), has also been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1]

Core Viewpoint - Kanghong Pharmaceutical's eye injection, Kangbaxip, has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, reflecting recognition of its innovation and clinical value by the National Healthcare Security Administration [1] Group 1: Product Inclusion - Kangbaxip is the only domestic innovative drug covering four major indications for retinal diseases in the current catalog [1] - The inclusion in the regular catalog management will enhance the stability and accessibility of medication for patients [1] Group 2: Ongoing Clinical Trials - The company is actively conducting Phase III clinical trials for high-dose Kangbaxip [1] - Clinical trials for gene therapy drugs KH631 and KH658 are being carried out in both China and the United States [1] - The aim is to benefit more patients through high-quality innovation [1]

Core Viewpoint - Kanghong Pharmaceutical's eye injection, Conbercept (brand name "Langmu"), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), reflecting the recognition of its innovative results and clinical value by the National Healthcare Security Administration [1] Group 1 - Conbercept is the only domestic innovative drug in the catalog that covers four major indications for retinal diseases [1] - The inclusion in the regular catalog management will enhance the stability and accessibility of medication for patients [1] - The company is actively conducting Phase III clinical trials for high-dose Conbercept and clinical trials for gene therapy drugs KH631 and KH658 in both China and the United States [1]

Group 1 - Aosaikang's product, Liraglutide tablets (brand name: Aoyixin®), has been included in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)" [1] - Kanghong Pharmaceutical's product, Conbercept eye injection (brand name: Langmu), has also been included in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025)" [1]

成都康弘药业集团股份有限公司 关于康柏西普眼用注射液被纳入国家医保目录的公告 证券代码：002773 证券简称：康弘药业 公告编号：2025-068 二、 风险提示 作为目前目录里唯一覆盖眼底病四大适应症的国产创新药，康柏 西普眼用注射液被纳入常规目录管理，体现了国家医保局对该品种创 新成果、临床价值、患者获益的认可，并将进一步提升患者用药的稳 定性和可及性。同时，公司也在积极开展康柏西普高剂量品种临床三 期试验，以及基因治疗药物 KH631、KH658 中美两地的临床试验，希 望通过高质量创新惠及更多患者。 新版《医保药品目录》于 2026 年 1 月 1 日起执行，具体到各统 筹地区和医保报销的等级医院的实施尚需时间，因此对公司当期经营 业绩的影响暂无法准确估计。敬请广大投资者谨慎决策，注意投资风 险。 特此公告。 成都康弘药业集团股份有限公司董事会 2025 年 12 月 7 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 国家医疗保障局网站于2025年12月7日发布《国家医保局 人力资 源社会保障部关于印发〈国家基本医疗保险、生育保险和工伤保险药 ...

Core Viewpoint - Kanghong Pharmaceutical (002773) confirmed that all currently marketed drugs have guaranteed supply from designated production bases [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - Assurance of supply indicates a stable operational capacity for the company's marketed products [1]

证券代码：002773 证券简称：康弘药业 公告编号：2025-065 成都康弘药业集团股份有限公司 关于变更公司注册资本及修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 03 日召开的第八届董事会第十四次会议审议通过了《关于变更公 司注册资本及修订<公司章程>的议案》，根据公司 2021 年股票期权激励 计划自主行权情况，公司拟变更注册资本、公司股份总数；同时，根据 《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章 程指引》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规、规 范性文件的要求，结合公司实际情况，同意删除《成都康弘药业集团股 份有限公司章程》（以下简称"《公司章程》"）中关于监事和监事会 的相关内容，由公司董事会审计委员会依法行使监事会的职权，《监事 会议事规则》相应废止，并对《公司章程》相应条款进行修订，具体如 下： | 序号 | 修订前 | | | | 修订后 ...